Meeting News

Three trials show efficacy of suprachoroidal CLS-TA injections for macular edema in uveitis

Eduardo Uchiyama

FORT LAUDERDALE, Fla. — Three clinical trials demonstrated rapid and sustained reduction of macular edema secondary to noninfectious uveitis in patients who received suprachoroidal CLS-TA, according to a speaker here.

“We found across all studies about 50% of all patients had a resolution of macular edema at 4 weeks,” Eduardo Uchiyama, MD, said at the Retina World Congress.

Uchiyama and colleagues pooled data from the DOGWOOD, PEACHTREE and AZALEA studies of patients with macular edema secondary to noninfectious uveitis. Patients received a suprachoroidal injection of CLS-TA (corticosteroid triamcinolone acetonide, Clearside Biomedical) at baseline, and resolution of macular edema was defined as central subfield thickness of less than 300 µm, Uchiyama said.

The PEACHTREE study included 96 patients, the AZALEA study included 20 patients, and the DOGWOOD study included 16 patients. The DOGWOOD study patients were followed for only 8 weeks. At week 12 in the PEACHTREE and AZALEA studies, patients were given a second injection.

Uchiyama said 54% of patients across all three studies experienced a resolution of macular edema at week 4 compared with 5% of sham patients.

At week 8, injection patients across all three studies experienced a 10 letter gain in best corrected visual acuity from baseline compared with a 1.7 letter gain in the sham cohort. At week 24, the combined patients in the AZALEA and PEACHTREE studies experienced an 11.9 letter gain from baseline compared with a 3 letter gain in the sham cohort, he said. by Robert Linnehan

 

Reference:

Uchiyama E. Suprachoroidal administration of CLS-TA: clinical trial results demonstrating rapid and sustained resolution of macula edema in uveitis patients. Presented at: Retina World Congress; March 21 to 24, 2019; Fort Lauderdale, Fla.

Disclosure: Uchiyama reports he receives consulting fees from Alcon and Novartis, is on the speakers bureau for AbbVie, and has contracted research with Clearside, Genentech and Novartis.

Eduardo Uchiyama

FORT LAUDERDALE, Fla. — Three clinical trials demonstrated rapid and sustained reduction of macular edema secondary to noninfectious uveitis in patients who received suprachoroidal CLS-TA, according to a speaker here.

“We found across all studies about 50% of all patients had a resolution of macular edema at 4 weeks,” Eduardo Uchiyama, MD, said at the Retina World Congress.

Uchiyama and colleagues pooled data from the DOGWOOD, PEACHTREE and AZALEA studies of patients with macular edema secondary to noninfectious uveitis. Patients received a suprachoroidal injection of CLS-TA (corticosteroid triamcinolone acetonide, Clearside Biomedical) at baseline, and resolution of macular edema was defined as central subfield thickness of less than 300 µm, Uchiyama said.

The PEACHTREE study included 96 patients, the AZALEA study included 20 patients, and the DOGWOOD study included 16 patients. The DOGWOOD study patients were followed for only 8 weeks. At week 12 in the PEACHTREE and AZALEA studies, patients were given a second injection.

Uchiyama said 54% of patients across all three studies experienced a resolution of macular edema at week 4 compared with 5% of sham patients.

At week 8, injection patients across all three studies experienced a 10 letter gain in best corrected visual acuity from baseline compared with a 1.7 letter gain in the sham cohort. At week 24, the combined patients in the AZALEA and PEACHTREE studies experienced an 11.9 letter gain from baseline compared with a 3 letter gain in the sham cohort, he said. by Robert Linnehan

 

Reference:

Uchiyama E. Suprachoroidal administration of CLS-TA: clinical trial results demonstrating rapid and sustained resolution of macula edema in uveitis patients. Presented at: Retina World Congress; March 21 to 24, 2019; Fort Lauderdale, Fla.

Disclosure: Uchiyama reports he receives consulting fees from Alcon and Novartis, is on the speakers bureau for AbbVie, and has contracted research with Clearside, Genentech and Novartis.

    See more from Retina World Congress